CytRx Corp (CYTR) Posts Q2 Loss of 28c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
- SanDisk upgraded at JPMorgan after investor day; shares climb
CytRx (CYTR) Still Trades at Favorable Valuation to Peers; Aegis Maintains 'Buy' Rating
August 7, 2014 11:28 AM EDTAegis Capital affirms its Buy rating and $12 target price on CytRx Corp. (Nasdaq: CYTR) following Q2 results and update.
Analyst Ram Selvaraju commented, The firm ended the quarter with $102.5mm in cash, which we expect to be sufficient to fund operations well into 2016, past a... More
CytRx (CYTR) Presents Significant Aldoxorubicin Phase 2b Data
August 7, 2014 6:09 AM EDTCytRx (Nasdaq: CYTR) announced that its oral presentation given by Sant P. Chawla, M.D., F.R.A.C.P., Director of the Sarcoma Oncology Center, titled Randomized phase 2b trial comparing first-line treatment with aldoxorubicin versus doxorubicin in patients with advanced soft tissue sarcomas, was featured in The Lancet Oncology in its July 2014 issue (Volume 15, Issue 8) in a review of the major presentations from the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting.
We are honored to have been included in The Lancet Oncologys... More
